FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036033631> ?p ?o ?g. }

• W2036033631 endingPage "6152" @default.
• W2036033631 startingPage "6141" @default.
• W2036033631 abstract "Abstract Purpose: Myxofibrosarcomas frequently display arm-level gains on 5p. We characterized the pathogenetic and therapeutic relevance of the α-methylacyl coenzyme A racemase (AMACR) at 5p13.3. Experimental Design: AMACR mRNA expression in myxofibrosarcomas was analyzed using the public transcriptome and laser-microdissected sarcoma cells. We performed florescence in situ hybridization (FISH) and immunohistochemistry in independent samples for clinical correlates. In AMACR-overexpressing myxofibrosarcoma cells and xenografts, we elucidated the biologic function of AMACR using RNA interference and explored the therapeutic effect and mechanism of an AMACR inhibitor, ebselen oxide. Results: AMACR protein overexpression and gene amplification were significantly associated with each other (P &lt; 0.001), with higher tumor grades (both P ≤ 0.002), and univariately with worse metastasis-free survival (MFS; both P &lt; 0.0001) and disease-specific survival (DSS; P = 0.0002 for overexpression; P = 0.0062 for amplification). AMACR protein overexpression also independently portended adverse outcome (DSS, P = 0.007; MFS, P = 0.001). However, 39% of AMACR-overexpression cases did not show gene amplification, implying alternative regulatory mechanisms. In myxofibrosarcoma cell lines, stable AMACR knockdown suppressed cell proliferation, anchorage-independent growth, and expression of cyclin D1 and cyclin T2. These growth-promoting attributes of AMACR were corroborated in the AMACR-silenced xenograft model and AMACR-underexpressed myxofibrosarcomas, showing decreased labeling for cyclin D1, cyclin T2, and Ki-67. Compared with fibroblasts, AMACR-expressing myxofibrosarcoma cells were more susceptible to ebselen oxide, which not only decreased viable cells, promoted proteasome-mediated degradation of AMACR protein, and induced cellular apoptosis in vitro, but also dose-dependently suppressed xenografted tumor growth in vivo. Conclusions: Overexpressed AMACR in myxofibrosarcomas can be amplification-driven, associated with tumor aggressiveness, and may be relevant as a druggable target. Clin Cancer Res; 20(23); 6141–52. ©2014 AACR." @default.
• W2036033631 created "2016-06-24" @default.
• W2036033631 creator A5003540257 @default.
• W2036033631 creator A5014734397 @default.
• W2036033631 creator A5017183258 @default.
• W2036033631 creator A5030175853 @default.
• W2036033631 creator A5030246175 @default.
• W2036033631 creator A5058286759 @default.
• W2036033631 creator A5069129723 @default.
• W2036033631 creator A5070326975 @default.
• W2036033631 creator A5071131195 @default.
• W2036033631 creator A5074883527 @default.
• W2036033631 creator A5082322430 @default.
• W2036033631 creator A5079692875 @default.
• W2036033631 date "2014-11-30" @default.
• W2036033631 modified "2023-10-02" @default.
• W2036033631 title "<i>AMACR</i> Amplification in Myxofibrosarcomas: A Mechanism of Overexpression That Promotes Cell Proliferation with Therapeutic Relevance" @default.
• W2036033631 cites W1974679405 @default.
• W2036033631 cites W1995345211 @default.
• W2036033631 cites W1996799445 @default.
• W2036033631 cites W2000657550 @default.
• W2036033631 cites W2000742564 @default.
• W2036033631 cites W2008055353 @default.
• W2036033631 cites W2010653328 @default.
• W2036033631 cites W2011298649 @default.
• W2036033631 cites W2022904488 @default.
• W2036033631 cites W2034652735 @default.
• W2036033631 cites W2035936829 @default.
• W2036033631 cites W2042006332 @default.
• W2036033631 cites W2044422474 @default.
• W2036033631 cites W2046024621 @default.
• W2036033631 cites W2049325706 @default.
• W2036033631 cites W2052486553 @default.
• W2036033631 cites W2054622999 @default.
• W2036033631 cites W2060204808 @default.
• W2036033631 cites W2061869862 @default.
• W2036033631 cites W2064157823 @default.
• W2036033631 cites W2068794572 @default.
• W2036033631 cites W2070196854 @default.
• W2036033631 cites W2081527842 @default.
• W2036033631 cites W2086797990 @default.
• W2036033631 cites W2092498599 @default.
• W2036033631 cites W2093285420 @default.
• W2036033631 cites W2095128237 @default.
• W2036033631 cites W2101448730 @default.
• W2036033631 cites W2116575688 @default.
• W2036033631 cites W2117692326 @default.
• W2036033631 cites W2134660396 @default.
• W2036033631 cites W2134972696 @default.
• W2036033631 cites W2135595576 @default.
• W2036033631 cites W2147721459 @default.
• W2036033631 cites W2148179062 @default.
• W2036033631 cites W2152269636 @default.
• W2036033631 cites W2156949267 @default.
• W2036033631 cites W2160253626 @default.
• W2036033631 cites W2313732289 @default.
• W2036033631 doi "https://doi.org/10.1158/1078-0432.ccr-14-1182" @default.
• W2036033631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25384383" @default.
• W2036033631 hasPublicationYear "2014" @default.
• W2036033631 type Work @default.
• W2036033631 sameAs 2036033631 @default.
• W2036033631 citedByCount "31" @default.
• W2036033631 countsByYear W20360336312015 @default.
• W2036033631 countsByYear W20360336312016 @default.
• W2036033631 countsByYear W20360336312017 @default.
• W2036033631 countsByYear W20360336312018 @default.
• W2036033631 countsByYear W20360336312019 @default.
• W2036033631 countsByYear W20360336312020 @default.
• W2036033631 countsByYear W20360336312021 @default.
• W2036033631 countsByYear W20360336312022 @default.
• W2036033631 countsByYear W20360336312023 @default.
• W2036033631 crossrefType "journal-article" @default.
• W2036033631 hasAuthorship W2036033631A5003540257 @default.
• W2036033631 hasAuthorship W2036033631A5014734397 @default.
• W2036033631 hasAuthorship W2036033631A5017183258 @default.
• W2036033631 hasAuthorship W2036033631A5030175853 @default.
• W2036033631 hasAuthorship W2036033631A5030246175 @default.
• W2036033631 hasAuthorship W2036033631A5058286759 @default.
• W2036033631 hasAuthorship W2036033631A5069129723 @default.
• W2036033631 hasAuthorship W2036033631A5070326975 @default.
• W2036033631 hasAuthorship W2036033631A5071131195 @default.
• W2036033631 hasAuthorship W2036033631A5074883527 @default.
• W2036033631 hasAuthorship W2036033631A5079692875 @default.
• W2036033631 hasAuthorship W2036033631A5082322430 @default.
• W2036033631 hasConcept C120089663 @default.
• W2036033631 hasConcept C153911025 @default.
• W2036033631 hasConcept C173396325 @default.
• W2036033631 hasConcept C190283241 @default.
• W2036033631 hasConcept C199835354 @default.
• W2036033631 hasConcept C29537977 @default.
• W2036033631 hasConcept C502942594 @default.
• W2036033631 hasConcept C54355233 @default.
• W2036033631 hasConcept C55493867 @default.
• W2036033631 hasConcept C62112901 @default.
• W2036033631 hasConcept C81885089 @default.
• W2036033631 hasConcept C86803240 @default.
• W2036033631 hasConceptScore W2036033631C120089663 @default.
• W2036033631 hasConceptScore W2036033631C153911025 @default.

• next